We reviewed the current situation of the 10 biggest biologic blockbusters, in terms of availability, sales, ongoing development, price and marketing strategy. It appears that this market is essentially concentrated in the US and EU5 and mainly focused on 2 therapeutic areas: cancer and autoimmune diseases. Biologics innovators are already under market pressure from biosimilar entrants in most global markets. Indeed a large number of patents are set to expire by 2020 and billions of dollars are predicted to be saved. This will create the opportunity for the development and approval of biosimilars. Even if there are still some unsolved scientific issues regarding criteria, design, and analysis for the assessment of biosimilarity and/or interchangeability with original drugs, it seems that we are entering a new era with a strong worldwide evolving of biosimilars. Most manufacturers remain focused on the developed markets; whether it is for their historic and current opportunities (EU) or for their future market potential (US, Japan). In the US biosimilars represent about 50% of the global biologics market value and generates about 50% of the sales value growth. It is also expected that biosimilars will reduce, in the US, direct spending on biologic drugs by $54 billion from 2017 to 2026, or about 3 percent of total estimated biologic spending over the same period, with a range of $24 to $150 billion. Emerging markets represent a very short part of total world biologic sales in value, less than seven to eight percent. While developed markets will remain an important focus area for biologics manufacturers, it appears clear that long-term growth likely will be drived by emerging markets. Emerging markets including the BRICS (Brazil, Russia, India, China and South Africa) and MIST (Mexico, Indonesia, South Korea and Turkey) countries.